160 related articles for article (PubMed ID: 36345897)
1. [Gene therapy for hereditary eye diseases].
Kessel L; Bertelsen M; Klemp K; Christensen UC
Ugeskr Laeger; 2022 Nov; 184(45):. PubMed ID: 36345897
[TBL] [Abstract][Full Text] [Related]
2. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
3. Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee.
Han J; Joo K; Kim US; Woo SJ; Lee EK; Lee JY; Park TK; Kim SJ; Byeon SH
Korean J Ophthalmol; 2023 Apr; 37(2):166-186. PubMed ID: 36950921
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
5. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
8. Frequency of
Kahraman NS; Öner A; Özkul Y; Dündar M
Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
[TBL] [Abstract][Full Text] [Related]
9. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
[TBL] [Abstract][Full Text] [Related]
10. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene.
Chung DC; Bertelsen M; Lorenz B; Pennesi ME; Leroy BP; Hamel CP; Pierce E; Sallum J; Larsen M; Stieger K; Preising M; Weleber R; Yang P; Place E; Liu E; Schaefer G; DiStefano-Pappas J; Elci OU; McCague S; Wellman JA; High KA; Reape KZ
Am J Ophthalmol; 2019 Mar; 199():58-70. PubMed ID: 30268864
[TBL] [Abstract][Full Text] [Related]
11. The first gene therapy for
Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
[TBL] [Abstract][Full Text] [Related]
12. Voretigene Neparvovec Gene Therapy in Clinical Practice: Treatment of the First Two Italian Pediatric Patients.
Testa F; Melillo P; Della Corte M; Di Iorio V; Brunetti-Pierri R; Citro A; Ferrara M; Karali M; Annibale R; Banfi S; Rossi S; Simonelli F
Transl Vis Sci Technol; 2021 Aug; 10(10):11. PubMed ID: 34554209
[TBL] [Abstract][Full Text] [Related]
13. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
[TBL] [Abstract][Full Text] [Related]
14. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.
Melillo P; Testa F; Di Iorio V; Karali M; Citro A; Della Corte M; Rossi S; Banfi S; Simonelli F
Ophthalmol Retina; 2024 Jul; 8(7):688-698. PubMed ID: 38295874
[TBL] [Abstract][Full Text] [Related]
15. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
Lopez J; Borchert M; Lee TC; Nagiel A
Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic
Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166
[TBL] [Abstract][Full Text] [Related]
17. RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec.
Stingl K; Priglinger C; Herrmann P
Klin Monbl Augenheilkd; 2024 Mar; 241(3):259-265. PubMed ID: 38508214
[TBL] [Abstract][Full Text] [Related]
18. [Gene Replacement Therapy for Inherited Retinal Dystrophies].
Mühlfriedel R; Sothilingam V; Tanimoto N; Seeliger MW
Klin Monbl Augenheilkd; 2017 Mar; 234(3):320-328. PubMed ID: 28355661
[TBL] [Abstract][Full Text] [Related]
19. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
[No Abstract] [Full Text] [Related]
20. Genetic Mutation Profiles in Korean Patients with Inherited Retinal Diseases.
Kim MS; Joo K; Seong MW; Kim MJ; Park KH; Park SS; Woo SJ
J Korean Med Sci; 2019 Jun; 34(21):e161. PubMed ID: 31144483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]